Fresenius, Europe’s biggest publicly traded health-care provider, said Friday that it’s in talks to buy US generic drugmaker Akorn.
While discussions are under way, there’s no certainty of a deal, said Fresenius, a maker of dialysis and medical products. The Germany-based company didn’t elaborate in a statement about the talks and a spokeswoman for Akorn declined to comment.
Akorn could complement Fresenius’s Kabi medicines division, which specializes in intravenous drugs, and accounts for about a fifth of the company’s revenue. Sturm said in February that the company could look at small-to-medium sized acquisitions to build up the business, and didn’t rule out larger deals.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI